Teriparatide

Displaying 1 - 3 of 3CSV
Ganapathy, A., Nieves, J. W., Keaveny, T. M., & Cosman, F. (2023). Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis. Bone, 167, 116618. https://doi.org/10.1016/j.bone.2022.116618
Publication Date
Agarwal, S., Shiau, S., Kamanda-Kosseh, M., Bucovsky, M., Kil, N., Lappe, J. M., Stubby, J., Recker, R. R., Guo, X. E., Shane, E., & Cohen, A. (2020). Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT. Journal of Bone and Mineral Research, 38(1), 35–47. https://doi.org/10.1002/jbmr.4739
Publication Date
Rooney, A. M., Dempster, D. W., Nieves, J. W., Zhou, H., Bostrom, M. P. G., & Cosman, F. (2022). Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck. Bone, 157, 116342. https://doi.org/10.1016/j.bone.2022.116342
Publication Date